Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability.
Sofinnova Partners invests across the entire value chain of life sciences investments, from seed to later-stage.
Sofinnova Partners was founded in 1972. The firm is headquartered in Paris, Ile-de-France, France, with offices in London and Milan.
Sofinnova actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Sofinnova closed of its latest early-stage healthcare venture capital fund, Sofinnova Capital X, oversubscribed at €472M ($548M) on Oct 19, 2021. This brings the total amount the VC has raised to €1 billion in the last 12 months across its multi-fund platform, and the total AUM to over €2.5B.
Sofinnova has backed over 500 companies, including Millennium Pharmaceuticals, Kosan Biosciences, Actelion, Intermune, Seattle Genetics, Cotherix, Threshold Pharmaceuticals, Prestwick, Preglem, and Movetis.